Navigation Links
Medicare Modernization Act not associated with major changes in access to chemotherapy
Date:7/8/2008

percent sample of claims from the Centers for Medicare & Medicaid Services for the period 2003 through 2006. Patients were Medicare beneficiaries with new breast cancer, colorectal cancer, leukemia, lung cancer, or lymphoma who received chemotherapy in inpatient hospital, institutional outpatient, or physician office settings. In this sample, there were 5,082 new cases of breast cancer, colorectal cancer, leukemia, lung cancer, or lymphoma in 2003; 5,379 cases in 2004; 5,116 cases in 2005; and 5,288 cases in 2006.

In each year, approximately 70 percent of patients had their first chemotherapy visit in a physician office, and no more than 10 percent received chemotherapy in an inpatient hospital setting. The distribution of treatment settings in 2003 was not significantly different from 2004; however, there was a small but significant difference between 2003 and 2006. The proportion of patients receiving chemotherapy in inpatient settings decreased from 10.2 percent in 2003 to 8.8 percent in 2006, and the proportion of patients in institutional outpatient settings increased from 21.1 percent to 22.5 percent. The proportion of patients in physician offices remained at 68.7 percent.

The median (midpoint) time from diagnosis to initial chemotherapy visit was 28 days in 2003, 27 days in 2004, 29 days in 2005, and 28 days in 2006. Average wait times for chemotherapy were 1.96 days longer in 2005 than in 2003 but not significantly different in 2006 (0.88 days). Median travel distance was 7 miles in 2003 and 8 miles in 2004 through 2006. After adjustment, average travel distance remained slightly longer in 2004 (1.47 miles), 2005 (1.19 miles), and 2006 (1.30 miles) compared with 2003.

"As measured by travel distance and time to chemotherapy, our findings do not support anecdotal reports that the enactment of the MMA has changed access to chemotherapy in a meaningful way. Given the slow transition to full implementation of the reimbursement change
'/>"/>

Contact: Michelle Gailiun
919-660-1306
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
3. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
7. Medicare Spending Caps Cause Seniors to Stop Meds
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Medicare Every Diabetic Counts Project Gears Up for Kick-Off
10. Medicare Cuts to Physicians Will Harm Washington Seniors
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... /PRNewswire-FirstCall/ -- HealthSouth,Corporation...previously,publicized investor meeting in New York...08 at 8:30 a.m. EST at the Grand Hyatt New York, l...ng is as follows:, 8:00 a.m. Continental Brea...f Executive Officer -- HealthSouth Ov...
(Date:10/6/2008)...y personnel and their family members can take,anon...nts, BOSTON, Oct. 6 /PRNewswire-USNewswire/ -- Mi...ers and their families that are unique and,difficu...tances matters get,worse and one problem can trigg...wise to check things out to see what is really hap...
(Date:10/6/2008)... at the University of California, San Diego School...upplements bolsters production of a protective che...vent skin infections that are a common result of a..., The study led by Richard Gallo, M.D., Ph.D., ... Dermatology at the UCSD School of Medicine and th...
(Date:10/6/2008)...ire/ -- A special supplement of the Oct. 15,journa... low- and,middle-income countries to implement bre...ommon disease among women worldwide., "Guidelines...l -,Implementation" developed by the Breast Health... of resource allocation -- based on countries,ove...
Breaking Medicine News(10 mins):Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3
...udies have shown that mapping the brain areas preo... of tumor surgery. A study that is to appear in t...stematically mapping the motor// and language area...c resonance imaging (fMRI), could help the surgeon...
...searchers from the University of Georgia have cond...to how the T cells in the body react to parasitic ...// A study led by scientists at the University of...d in the online journal PLOS Pathogens, which is a...
... Researchers believe that the transfusions of bloo...e the number of deaths due to bird flu in case of ...during the Spanish flu pandemic of 1918-1920, the ...ns from people who had recovered had improved the ...
...venscourt Park Hospital, which was described as be...d for the lack of patients. Hammersmith Hospitals ...02. At that time ministers had predicted that the...ve surgery. Ravenscourt Park, which had six theatr...
Other Medicine News:Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 2Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 3
(Date:10/6/2008)... - Data Presented at ACG Annual Scientific C...- Ironwood Pharmaceuticals,(formerly Microbia) tod...reclinical studies delineating the role that cycli...ing intestinal pain. These studies,demonstrate tha...odel of,intestinal hyperalgesia and desensitizes c...
(Date:10/6/2008)... Results from Phase 3b Studies with Durezol Dosed .../ -- Sirion Therapeutics, Inc., a,privately held o...nced,today that Durezol(TM) (difluprednate ophthal... Durezol, which was approved by the U.S. Food and,...thalmic corticosteroid,indicated for the treatment...
(Date:10/6/2008)...More than 60 percent of moderate to severe patient...rcent achieved endoscopic remission at Week 10,in ...the American College,of Gastroenterology (ACG) Ann...Newswire/ -- UCB today presented data from a,large...vement in Crohn,s,disease (CD) with a biologic com...
(Date:10/6/2008)...SEATTLE, Oct. 6 /- Dendreon... call today, Monday, October 6, 2008 at 9:00 AM,ET... analysis of its IMPACT,(IMmunotherapy for Prostat...clinical trial of PROVENGE(R) (sipuleucel-T), the ...erapy for the treatment of advanced prostate,cance...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 1TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 2TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 3ICERx org Activated to Provide Emergency Access to Prescription Medication Information for Hurricane Gustav Evacuees 25915 1American Red Cross Relief Efforts Underway for Gustav 25910 1American Red Cross Relief Efforts Underway for Gustav 25910 2New master switch found in the brain that regulates appetite and reproduction 4655 1New master switch found in the brain that regulates appetite and reproduction 4655 2New master switch found in the brain that regulates appetite and reproduction 4655 3New master switch found in the brain that regulates appetite and reproduction 4655 4
...ire-FirstCall/ - Bradmer,Pharmaceuticals Inc., a b...ent and commercialization of cancer therapies, tod...ependent team in,Basel, Switzerland validates tena...lopment of new treatments for glioblastoma,multifo...oss of NOTCH2 gene,positively predicts survival in...
...2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) announced... target patient enrollment and released six-month,...n as Appraisal.,The trial, currently being held in...Neugene(R) antisense drug Resten-MP(TM), when,used...bare metal,stents, in the prevention of cardiovasc...
Other Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches.
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches.
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required.
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches.
Medicine Products: